Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America

NEXT STORY
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
PREV STORY
Kuwait Retail Pharmacy Market Outlook to 2022: Growth Drivers, Trends, and Developments
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China

First study of niraparib for this indication worldwide; a significant medical need in China  ...

author_avatar
NASDAQ Market News

Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives

author_avatar
NASDAQ Market News

Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex™-exatecan)

author_avatar
NASDAQ Market News